Entera Bio Ltd (ENTX) News
Filter ENTX News Items
ENTX News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
ENTX News Highlights
- ENTX's 30 day story count now stands at 2.
- Over the past 27 days, the trend for ENTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ENTX are BIO, DEC and NOV.
Latest ENTX News From Around the Web
Below are the latest news stories about ENTERA BIO LTD that investors may wish to consider to help them evaluate ENTX as an investment opportunity.
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025JERUSALEM, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with certain existing and new investors. The Company issued and sold 7,916,879 units at a price of $0.835 per unit, each consisting of one ordinary share of Entera (or one pre-funded warrant in lieu thereof), and one five-year warrant. Gross pr |
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide PlatformJERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported today interim data from an ongoing Phase 1 study designed to assess and compare the pharmacokinetic (PK) and early pharmacodynamic (PD) profile of current and several next generation compositions of its oral peptide platform (NCT05965167). EB613 Continues to Display an Optimal Profile as First-in-Class |
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in DevelopmentJERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial results for the third quarter ended September 30th, 2023. “Today, after over a year of steadfast transformation and execution, Entera stands as a premier oral peptide company. It is our goal to potentially move five high value, first-in-class programs, Phase |
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for OsteoporosisJERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that the American Society for Bone and Mineral Research (ASBMR) has announced that the SABRE (Strategy to Advance BMD as a Regulatory Endpoint) project team has submitted to the U.S. Food and Drug Administration (FDA) its full qualification plan to use the treatment-related change in bone mineral |
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual MeetingJERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented 2 posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting held on October 13-16, 2023 in Vancouver, BC, Canada. Both posters will be available on the Company’s website, www.enterabio.com. “Entera’s ability to consistently deliver our oral PTH(1-34) peptide in a simple mi |
OPKO Health (OPK) Ties Up for Oral Peptide Tablet FormulationsOPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides. |
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption SyndromesJERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera’s proprietary oral delivery technology. It is challenging to administer peptides or |
Entera Bio to Participate in Upcoming Investor ConferencesJERUSALEM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it will participate in the upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference September 11-13th Presentation: Monday September 11th, 7:00am ETPresenter: Miranda Toledano, CEOLocation: New York, NYWebcast Link: https://journey.ct.events BIO Investor Foru |
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although... |
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual MeetingJERUSALEM, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting on October 13-16, 2023 in Vancouver, BC, Canada. EB613 [hPTH(1-34) tablets] is being developed as the first once-daily oral anabolic (bone forming) mini tablet therapy for post-menopaus |